RecruitingNCT05434325
TESTING -ON Post-Trial ObservatioNal Cohort Study
Therapeutic Evaluation of STeroids in IgA Nephropathy Global - Post-Trial ObservatioNal Cohort Study
Sponsor
The George Institute
Enrollment
366 participants
Start Date
Dec 7, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
The primary aim of this study is to extend follow up of TESTING study participants and to assess the long-term effects of a 6-9-month course of oral methylprednisolone on End Stage Kidney Disease (ESKD), according to dose (full-dose vs reduced-dose), ethnicity (Chinese vs other) and kidney function (eGFR above and below 60 mL/min/1.73m2).
Eligibility
Min Age: 18 YearsMax Age: 100 Years
Inclusion Criteria1
- \) Only participants who were randomised into the TESTING trial
Exclusion Criteria4
- Participants who have reached kidney failure requiring maintenance dialysis or kidney transplantation during the TESTING trial
- Participants who died during the TESTING trial
- Participants who had withdrawn their consent during the TESTING trial
- Participants who are unable to provide consent for some other reason
Locations(58)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05434325
Related Trials
Collaborative Learning to Achieve Refined Interventions for Emory: Kidney Disease
NCT066936611 location
Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis
NCT069136471 location
Archival of Human Biological Samples in CU-Med Biobank
NCT047064811 location
Study of BHV-1400 in IgA Nephropathy
NCT0705468412 locations
Transformative Research in Diabetic Nephropathy 2.0
NCT074442031 location